MVP and cancer: These changes probably affect cancer signaling pathways and lung-resistance related protein, which are significant in the effectiveness of epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib, used in cancer treatment [84].